Ciclopirox


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Topical Seborrhoeic dermatitis As 1% ciclopirox base shampoo: Apply 5-10 mL unto the scalp twice weekly for 4 weeks, with a Min of 3 days between application. Nail fungal infections As 8% lacquer: Apply once daily. Skin fungal infections As 0.77% (ciclopirox base) cream/gel/suspension/solution: Apply onto affected areas bid.
Dosage Details
Topical/Cutaneous
Seborrhoeic dermatitis
Adult: As 1% ciclopirox base shampoo: Apply 5-10 mL unto the scalp twice weekly for 4 weeks, with a Min of 3 days between application.

Topical/Cutaneous
Skin fungal infections
Adult: As 0.77% (ciclopirox base) cream/gel/suspension/solution: Apply onto affected areas bid.

Topical/Cutaneous
Nail fungal infections
Adult: As 8% (ciclopirox base) lacquer: Apply onto the affected nails once daily.
Contraindications
Hypersensitivity; occlusive wrappings/dressings.
Special Precautions
Children <10 yr; pregnancy, lactation. Avoid contact with eyes. For external use only.
Adverse Reactions
Pruritus, burning sensation; headache, rash, irritation, dryness.
Action
Description: Ciclopirox has a wide spectrum of antifungal activity and some antibacterial activity. Inhibits most Candida, Epidermophyton, Microsporum, Trichophyton species and M. furfur by inhibiting transport of essential elements in fungal cells, thus disrupting DNA, RNA and protein synthesis.
Pharmacokinetics:
Absorption: <2% through intact skin (topical).
Distribution: To epidermis, corium (dermis), including hair, hair follicles and sebaceous glands. Protein-binding: 94-98%.
Excretion: Urine, faeces (small amounts). Elimination half-life: 1.7 hr (solution); 5.5 hr (gel).
Storage
Store between 15-30°C.
Disclaimer: This information is independently developed by MIMS based on Ciclopirox from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Tolnaderm AI
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in